Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

Benzinga Newsdesk www.benzinga.com Positive 78.6%

Neg 0% Neu 0% Pos 78.6%

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $281 to $286.